Aliases & Classifications for Raynaud Phenomenon

MalaCards integrated aliases for Raynaud Phenomenon:

Name: Raynaud Phenomenon 43 70
Raynaud Disease 43 70
Raynaud's 43 62
Secondary Raynaud's Phenomenon 70
Raynaud's Phenomenon 43
Raynauds Phenomenon 54
Raynaud's Syndrome 43
Raynaud's Disease 43

External Ids:

UMLS 70 C0034734 C0034735 C1282916

Summaries for Raynaud Phenomenon

MedlinePlus Genetics : 43 Raynaud phenomenon is a condition in which the body's normal response to cold or emotional stress is exaggerated, resulting in abnormal spasms (vasospasms) in small blood vessels called arterioles. The disorder mainly affects the fingers but can also involve the ears, nose, nipples, knees, or toes. The vasospasms reduce blood circulation, leading to discomfort and skin color changes.Raynaud phenomenon is episodic, meaning that it comes and goes. A typical episode lasts about 15 minutes after the cold exposure or stressor has ended and involves mild discomfort such as numbness or a feeling of "pins and needles." The affected areas usually turn white or blue when exposed to cold or when emotional stress occurs, and then turn red when re-warmed or when the stress eases.Raynaud phenomenon is categorized as primary when there is no underlying disorder that accounts for the exaggerated response of the blood vessels. It is called secondary when it is associated with another condition. Secondary Raynaud phenomenon is often associated with autoimmune disorders, which occur when the immune system malfunctions and attacks the body's own tissues and organs. Autoimmune disorders with which Raynaud phenomenon can be associated include systemic lupus erythematosus, scleroderma, rheumatoid arthritis, and Sjögren syndrome.Primary Raynaud phenomenon is much more common and usually less severe than secondary Raynaud phenomenon. In severe cases of secondary Raynaud phenomenon, sores on the pads of the fingers or tissue death (necrosis) can occur. Primary Raynaud phenomenon often begins between the ages of 15 and 25, while secondary Raynaud phenomenon usually starts after age 30. Some people with Raynaud phenomenon alone later go on to develop another associated condition; regardless of which comes first, these cases are classified as secondary Raynaud phenomenon.

MalaCards based summary : Raynaud Phenomenon, also known as raynaud disease, is related to systemic scleroderma and raynaud disease, and has symptoms including nausea and vomiting, constipation and fatigue. An important gene associated with Raynaud Phenomenon is ADRA2C (Adrenoceptor Alpha 2C). The drugs Cilostazol and Acetylcholine have been mentioned in the context of this disorder. Affiliated tissues include endothelial, tongue and spinal cord, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

PubMed Health : 62 About raynaud's: Raynaud's is a rare disorder that affects the arteries. Arteries are blood vessels that carry blood from your heart to different parts of your body. Raynaud's sometimes is called a disease, syndrome, or phenomenon. The disorder is marked by brief episodes of vasospasm (VA-so-spazm), which is a narrowing of the blood vessels. Vasospasm of the arteries reduces blood flow to the fingers and toes. In people who have Raynaud's, the disorder usually affects the fingers. In about 40 percent of people who have Raynaud's, it affects the toes. Rarely, the disorder affects the nose, ears, nipples, and lips.

Related Diseases for Raynaud Phenomenon

Diseases related to Raynaud Phenomenon via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 429)
# Related Disease Score Top Affiliating Genes
1 systemic scleroderma 31.8 EDN1 CENPB
2 raynaud disease 31.7 EDN1 CENPB ADRA2C
3 scleroderma, familial progressive 30.9 EDN1 CENPB
4 connective tissue disease 29.9 EDN1 CENPB APOH
5 diffuse scleroderma 29.7 EDN1 CENPB
6 limited scleroderma 29.7 EDN1 CENPB
7 buerger disease 29.4 EDN1 APOH
8 hellp syndrome 29.2 EDN1 APOH
9 angiopathy, hereditary, with nephropathy, aneurysms, and muscle cramps 11.4
10 undifferentiated connective tissue disease 11.3
11 antisynthetase syndrome 11.3
12 vasculopathy, retinal, with cerebral leukoencephalopathy and systemic manifestations 11.1
13 reynolds syndrome 11.1
14 moyamoya disease 6 with or without achalasia 11.1
15 waldenstroem's macroglobulinemia 11.1
16 sting-associated vasculopathy with onset in infancy 11.1
17 retinal vasculopathy with cerebral leukodystrophy with systemic manifestations 11.0
18 linear scleroderma 10.9
19 simple cryoglobulinemia 10.9
20 migraine with or without aura 1 10.3
21 pulmonary hypertension 10.2
22 vascular disease 10.2
23 cyanosis, transient neonatal 10.2
24 crest syndrome 10.2
25 telangiectasis 10.2
26 calcinosis 10.2
27 purpura 10.2
28 systemic lupus erythematosus 10.1
29 helicobacter pylori infection 10.1
30 exanthem 10.1
31 igg4-related disease 10.1
32 antiphospholipid syndrome 10.1
33 mixed connective tissue disease 10.1
34 vasculitis 10.1
35 perniosis 10.1
36 paraneoplastic syndromes 10.1
37 paresthesia 10.1
38 headache 10.1
39 rheumatoid arthritis 10.1
40 angina pectoris 10.0
41 hereditary hemorrhagic telangiectasia 10.0
42 horner's syndrome 10.0
43 arthritis 10.0
44 anorexia nervosa 10.0
45 thrombosis 10.0
46 testicular cancer 10.0
47 interstitial lung disease 10.0
48 myopathy 10.0
49 atrial standstill 1 9.9
50 multiple sclerosis 9.9

Comorbidity relations with Raynaud Phenomenon via Phenotypic Disease Network (PDN):

Deficiency Anemia Esophagitis
Hypertension, Essential Hypothyroidism
Peripheral Vascular Disease Systemic Lupus Erythematosus
Systemic Scleroderma

Graphical network of the top 20 diseases related to Raynaud Phenomenon:

Diseases related to Raynaud Phenomenon

Symptoms & Phenotypes for Raynaud Phenomenon

UMLS symptoms related to Raynaud Phenomenon:

nausea and vomiting; constipation; fatigue; fever; angina pectoris; abdominal pain; chest pain; headache; pruritus; syncope; diarrhea; edema; pain; chronic pain; sciatica; halitosis; dyspepsia; icterus; coughing; vertigo/dizziness; symptoms; heartburn; gastrointestinal gas; pelvic pain; cold intolerance; joint or joint related complaint

GenomeRNAi Phenotypes related to Raynaud Phenomenon according to GeneCards Suite gene sharing:

26 (show all 17)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-123 9.61 APOH
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-179 9.61 APOH
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-2 9.61 EDN1
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-200 9.61 EDN1
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-55 9.61 APOH
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-58 9.61 EDN1
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-63 9.61 APOH
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-70 9.61 APOH
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-88 9.61 APOH
10 Increased shRNA abundance (Z-score > 2) GR00366-A-141 9.23 APOH
11 Increased shRNA abundance (Z-score > 2) GR00366-A-159 9.23 EDN1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-173 9.23 EDN1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-25 9.23 EDN1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-42 9.23 EDN1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-70 9.23 EDN1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-88 9.23 EDN1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-91 9.23 EDN1

MGI Mouse Phenotypes related to Raynaud Phenomenon:

# Description MGI Source Accession Score Top Affiliating Genes
1 mortality/aging MP:0010768 9.02 ADRA2C APOH CENPB EDN1 LBR

Drugs & Therapeutics for Raynaud Phenomenon

PubMed Health treatment related to Raynaud Phenomenon: 62

Primary Raynaud 's (Raynaud's disease) and secondary Raynaud's (Raynaud's phenomenon) have no cure. However, treatments can reduce the number and severity of Raynaud's attacks. Treatments include lifestyle changes, medicines, and, rarely, surgery . Most people who have primary Raynaud 's can manage the condition with lifestyle changes. People who have secondary Raynaud's may need medicines in addition to lifestyle changes. Rarely, they may need surgery or shots . If you have Raynaud 's and develop sores on your fingers , toes, or other parts of your body, see your doctor right away. Timely treatment can help prevent permanent damage to these areas.

Drugs for Raynaud Phenomenon (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 123)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
3 Platelet Aggregation Inhibitors Phase 4
4 Respiratory System Agents Phase 4
5 Phosphodiesterase 3 Inhibitors Phase 4
6 Fibrinolytic Agents Phase 4
7 Anti-Asthmatic Agents Phase 4
8 Bronchodilator Agents Phase 4
9 abobotulinumtoxinA Phase 4
10 Neurotransmitter Agents Phase 4
11 Cholinergic Agents Phase 4
12 Botulinum Toxins Phase 4
13 Botulinum Toxins, Type A Phase 4
14 Pharmaceutical Solutions Phase 4
Iloprost Approved, Investigational Phase 3 78919-13-8 6443959
Nifedipine Approved Phase 3 21829-25-4 4485
Amlodipine Approved Phase 2, Phase 3 88150-42-9 2162
Udenafil Approved, Investigational Phase 2, Phase 3 268203-93-6 6918523
Nitroglycerin Approved, Investigational Phase 3 55-63-0 4510
Sodium citrate Approved, Investigational Phase 2, Phase 3 68-04-2
Prilocaine Approved Phase 3 721-50-6 4906
Lidocaine Approved, Vet_approved Phase 3 137-58-6 3676
Nitrous oxide Approved, Vet_approved Phase 3 10024-97-2 948
Bupivacaine Approved, Investigational Phase 2, Phase 3 2180-92-9, 38396-39-3 2474
St. John's Wort Approved, Investigational, Nutraceutical Phase 3 84082-80-4
Citric acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 77-92-9 311
Fasudil Investigational Phase 3 103745-39-7
28 Phosphodiesterase Inhibitors Phase 3
29 Phosphodiesterase 5 Inhibitors Phase 2, Phase 3
30 Vasodilator Agents Phase 3
31 Calcium, Dietary Phase 3
32 Antihypertensive Agents Phase 2, Phase 3
33 Sildenafil Citrate Phase 2, Phase 3 171599-83-0
34 calcium channel blockers Phase 3
35 Citrate Phase 2, Phase 3
36 Tocolytic Agents Phase 3
37 Protein Kinase Inhibitors Phase 3
38 Vardenafil Dihydrochloride Phase 2, Phase 3
39 insulin Phase 3
40 Insulin, Globin Zinc Phase 3
41 Chelating Agents Phase 3
42 Anticoagulants Phase 3
43 Anesthetics Phase 2, Phase 3
44 Anesthetics, Local Phase 2, Phase 3
Calcium Nutraceutical Phase 3 7440-70-2 271
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
Atorvastatin Approved Phase 2 134523-00-5 60823
Alprostadil Approved, Investigational Phase 2 745-65-3 149351 5280723
Riociguat Approved Phase 2 625115-55-1
Selexipag Approved Phase 2 475086-01-2

Interventional clinical trials:

(show top 50) (show all 76)
# Name Status NCT ID Phase Drugs
1 Safety and Efficacy of Pletal (Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud's Phenomenon Completed NCT00048776 Phase 4 Pletal
2 Safety and Efficacy of Pletal(Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud's Phenomenon Completed NCT00048763 Phase 4 Pletal
3 The Effect of Abobotulinum Toxin A on the Symptoms of Raynaud's Phenomenon, a Double-Blind Randomized Placebo-Controlled Trial Terminated NCT03639766 Phase 4 AbobotulinumtoxinA
4 A Study of a Topical Formulation of Nitroglycerin, MQX-503, and Matching Vehicle in the Treatment and Prevention of Raynaud's Phenomenon Unknown status NCT00577304 Phase 3 Nitroglycerin;Topical AmphiMatrix
5 A Study of a Topical Formulation of Nitroglycerin, Vascana® (MQX-503), and Matching Vehicle in the Treatment and Prevention of Symptoms Associated With Raynaud's Phenomenon Unknown status NCT00934427 Phase 3 0.9% nitroglycerin in TAM cream;vehicle cream
6 Comparison of Phosphodiesterase-5 Inhibitor and Calcium Channel Inhibitor for the Treatment of Secondary Raynaud Phenomenon, Double Blind, Randomized, Cross-over Trial Completed NCT01280266 Phase 2, Phase 3 Udenafil or Amlodipine
7 A Randomized, Placebo-controlled Trial of St.John's Wort(a Natural Health Product) in the Treatment on Raynaud's Phenomenon Completed NCT00351117 Phase 3 St. John's Wort;Lactose
8 Phase III "In-Life" Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, and Matching Placebo Gel in the Treatment and Prevention of Raynaud's Phenomenon Completed NCT00419419 Phase 3 Topical AmphiMatrix with nitroglycerin (MQX-503)
9 Phase III "in-Life" Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, and Matching Placebo Gel in the Treatment and Prevention of Raynaud's Phenomenon Completed NCT00266669 Phase 3 Topical organogel with nitroglycerin
10 Phase III Laboratory Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, in the Treatment of Raynaud's Phenomenon Completed NCT00253331 Phase 2, Phase 3 topical organogel with nitroglycerin
11 Randomised Control Trial to Assess the Efficacy of Tadalafil in Raynaud's Phenomenon in Scleroderma Completed NCT00626665 Phase 3 Tadalafil
12 A Randomized Control Trial to Assess the Efficacy of Tadalafil in Raynaud's Phenomenon in Scleroderma: A Double Blind, Parallel Group, Multicentric Study Completed NCT01117298 Phase 3 Tadalafil;Placebo
13 Efficacy and Safety of "as Required" Sildenafil for Patients With Moderate to Severe Raynaud's Phenomenon (RP) Completed NCT02050360 Phase 2, Phase 3 Sildenafil 40 mg;Sildenafil 80 mg;Placebo
14 Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Study to Assess Efficacy of Botulinum Toxin A in Adult Subjects With Raynaud Phenomenon Secondary to Systemic Sclerosis Completed NCT03717961 Phase 3 BOTOX® solution;Placebo group
15 Phase III Randomized, Double-Blind, Placebo-Controlled Study of Oral Iloprost for Raynaud's Phenomenon Secondary to Systemic Sclerosis Completed NCT00004786 Phase 3 iloprost
16 Efficacy, Tolerability and Biology of a Rho-kinase Inhibitor (Fasudil) in the Treatment of Raynaud's Phenomenon Completed NCT00498615 Phase 3 Fasudil
17 Double-blind, Placebo-controlled Cross-over Study to Investigate the Effects of the Phosphodiesterase 5-inhibitor Vardenafil on Periphery Blood Flow and Clinical Symptoms of Patients With Raynaud's Syndrome Completed NCT01291199 Phase 2, Phase 3 vardenafil;Placebo
18 A Randomized, Double-Blinded, Placebo-Controlled Clinical Trial Assessing the Therapeutic Efficacy of Botulinum Toxin In Treating Scleroderma-Associated Raynaud's Syndrome Completed NCT02165111 Phase 3 Onabotulinumtoxin A;sterile saline solution
19 Raynaud's Treatment Study (RTS) Completed NCT00000530 Phase 3 nifedipine
20 Effect of Sildenafil on the Microcirculatory Blood Flow and on the Endothelial Progenitor Cells in Patients With Systemic Sclerosis: a Randomized, Double-blind, Placebo-controlled Clinical Trial Completed NCT01347008 Phase 3 Sildenafil citrate;Placebo (Sugar pill)
21 A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study Evaluating the Safety and Efficacy of Intravenous Iloprost in Subjects With Systemic Sclerosis Experiencing Symptomatic Digital Ischemic Episodes (AURORA Study) Active, not recruiting NCT04040322 Phase 3 Placebo IV infusion;Iloprost Injection, for intravenous use
22 Chemical Sympathectomy Following Peripheral Nerve Block With Liposomal Bupivacaine Terminated NCT02374320 Phase 2, Phase 3 liposomal bupivacaine
23 Safety and Efficacy Study of Pl-vegf165 to Treat Secondary Raynaud's Phenomenon Caused by Systemic Scleroderma Unknown status NCT02356809 Phase 1, Phase 2 Neovasculgen
24 A 28-Day Randomized, Double-Blind, Placebo-Controlled Clinical Trial and 5-Year Prospective Outcomes Study: A Two-Part Study of BOTOX® Therapy for Ischemic Digits Completed NCT01309802 Phase 2 onabotulinum toxin type-A
25 A Phase 2a Randomized Double-blinded, Placebo And Active Controlled Two Cohort Two Doses Cross-over Multi-center Clinical Study To Assess Efficacy Of A Once Daily Administration Of A Phosphodiesterase 5 Inhibitor (Pf-00489791) For The Treatment Of Vasospasm In Primary And Secondary Raynaud's Phenomenon Completed NCT01090492 Phase 2 PF-00489791;PF-00489791;PF-00489791;PF-00489791;PF-00489791;PF-00489791;PF-00489791;PF-00489791
26 A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 2 Pilot Study Evaluating Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis Completed NCT03867097 Phase 2 Placebo IV infusion;Iloprost Injection, for intravenous use
27 Randomized, Placebo-Controlled, Double-Blind, Cross-Over Trial of the Efficacy and Safety of IC351 in Female Patients With Raynaud Phenomenon and Female Sexual Dysfunction Secondary to Systemic Sclerosis Completed NCT00707187 Phase 2 Cialis
28 Phase II Dose Response Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, in the Treatment of Raynaud's Phenomenon Completed NCT00378521 Phase 2 MQX-503
29 Phase II Dose Response Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, in the Treatment of Raynaud's Phenomenon Completed NCT00480753 Phase 2 Nitroglycerin
30 Single Dose, Double-blind, Placebo-controlled, Single Center, Randomized Cross-over Study to Investigate Safety, Tolerability, Pharmacodynamics and Pharmacokinetic Properties of BAY63-2521 After Oral Dosing in 20 Patients With Raynaud's Phenomenon (RP) Completed NCT01926847 Phase 2 Riociguat (Adempas, BAY63-2521);Placebo
31 A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group, Exploratory Phase 2 Study to Assess Efficacy and Safety of Selexipag in Adult Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis Completed NCT02260557 Phase 2 Selexipag;Placebo
32 A Double-blinded Crossover Study of Topical Formulation of Nitroglycerine, Vascana®, Versus Matching Vehicle in the Subjective and Physiologic Responses to Controlled Cold Challenge in Subjects With Raynaud's Phenomenon (RP) Secondary to Connective Tissue Disease Completed NCT02688270 Phase 2 Vascana (0.9% nitroglycerin cream);Vehicle (placebo)
33 A Phase 2a Double-Blind, Randomized, Placebo-Controlled Crossover Trial of the Acute Peripheral Vascular Effects, Safety and Tolerability of Alprostadil Topical Cream in Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis (SSc, Scleroderma) Completed NCT02228850 Phase 2 Alprostadil
34 A Phase 2, Single-center, Randomised, Double-blind, Placebo-controlled, Cross-over Cold Challenge Study Investigating the Effect of C21 on Cold-induced Vasoconstriction in Subjects With Raynaud's Phenomenon (RP) Secondary to Systemic Sclerosis (SSc) Completed NCT04388176 Phase 2 C21;C21;Placebo;Placebo
35 A Randomized, Double Blind, Placebo-controlled, Cross-over Pilot Study to Examine the Safety, Tolerability and Pharmacodynamic Profile of Repeat Oral Doses of SLx-2101 Once Daily for up to 14 Days in Subjects With Secondary Raynaud's Disease. Completed NCT00528242 Phase 2 SLx-2101;Placebo
36 Efficacy and Tolerability of Ginkgo Biloba Extract EGb 761® in Patients With Raynaud´s Phenomenon Completed NCT00251238 Phase 2 Ginkgo biloba extract EGb 761
37 The Effect of Atorvastatin on Microvascular Endothelial Function and Raynaud in Early Diffuse Systemic Sclerosis Completed NCT02370784 Phase 2 atorvastatin;Placebo
38 A Phase II, Randomized, Multi-center, Placebo-controlled, Double-blind Study to Investigate the Safety of GS-248, and Efficacy on Raynaud's Phenomenon (RP) and Peripheral Vascular Blood Flow, in Subjects With Systemic Sclerosis (SSc) Recruiting NCT04744207 Phase 2 GS-248;Placebo
39 Phase IIa Study of the Efficacy of ORM-12471 for Prevention of Cold-induced Vasospasm: a Randomised, Double-blind, Placebo-controlled, Single Centre Crossover Study in Patients With Raynaud's Phenomenon Secondary to Systemic Sclerosis Terminated NCT01315899 Phase 2 ORM-12471 30mg;ORM-12471;placebo
40 MXQ-503 Applied To The Hand Vs. Nitroglycerin Ointment 2%, USP, Applied To The Chest: A Pharmacokinetic Comparison In Normal Subjects Completed NCT00841594 Phase 1 nitroglycerin 0.9 % (MXQ-503);Nitroglycerin ointment 2%, USP
41 A Phase I Trial of the Pharmacodynamic Dose Response to Topical Trinitrate in Patients With Raynaud's Phenomenon Completed NCT00700518 Phase 1 placebo cream;Glyceryl Trinitrate;Glyceryl Trinitrate;Glyceryl Trinitrate;Glyceryl Trinitrate
42 Monocenter, IIT, Open Controlled and Prospectiv Study to Define the Prognostic Influence of Light Rheography Measurement of Patients With Secundary Raynaud Syndrome With Ulcers at Fingertips Throughout the Medicinal Therapy Unknown status NCT01378845 Tracleer;Prostavasin
43 Rôle Des Acides Epoxy-eicosatriénoïques et du Monoxyde d'Azote Dans l'hyperhémie Post-occlusive cutanée Digitale et la réponse cutanée au Froid Dans le phénomène de Raynaud Primaire Unknown status NCT02183779 L-NMMA and Fluconazole dermic injection
44 RaynAUT - Thermography and the Autonomic Nervous System in Raynaud's Phenomenon - Investigation of the Autonomic Nervous System in Patients With Raynaud's Phenomenon, Glaucoma, and Autonomic Neuropathy. Completed NCT03094910
45 Diosmiplex (Vasculera®) in Primary and Secondary Raynaud's Phenomenon Completed NCT02683408
46 Prospective Multicenter Study on the Identification of Genetic Abnormalities Predisposing to Vasospasm From a Privileged Model: the Primary Raynaud's Phenomenon Completed NCT02202291
47 Identification of Transient Receptor Potential (TRP) Channels as New Potential Therapeutic Targets in Primary and Secondary Raynaud's Phenomenon. Completed NCT03211325
48 Tadalafil for the Treatment of Secondary Raynaud's Phenomenon Completed NCT00822354 Tadalafil
49 A Randomized, Single-blinded Placebo-controlled Trial of Ischemic Preconditioning in Raynaud's Phenomenon (RP) Completed NCT02506062
50 "Color Doppler Ultrasound Comparison of Topical 10 % Nifedipine Versus 5% Sildenafil in Secondary Raynaud: A Randomized, Double-blind, Placebo-controlled Pilot Study" Completed NCT03027674 Early Phase 1 10% nifedipine cream;5% sildenafil cream

Search NIH Clinical Center for Raynaud Phenomenon

Inferred drug relations via UMLS 70 / NDF-RT 51 :

Isoxsuprine Hydrochloride
Papaverine Hydrochloride
Prazosin hydrochloride
Tolazoline Hydrochloride

Genetic Tests for Raynaud Phenomenon

Anatomical Context for Raynaud Phenomenon

MalaCards organs/tissues related to Raynaud Phenomenon:

Endothelial, Tongue, Spinal Cord, Skin, Smooth Muscle, Bone Marrow, Neutrophil

Publications for Raynaud Phenomenon

Articles related to Raynaud Phenomenon:

(show top 50) (show all 6817)
# Title Authors PMID Year
Secondary Sjogren's syndrome in systemic lupus erythematosus defines a distinct disease subset. 61 54
20360189 2010
[A clinical study of femoral head osteonecrosis in patients with systemic lupus erythematosus.]. 61 54
20079323 2009
Potential biomarkers for detecting pulmonary arterial hypertension in patients with systemic sclerosis. 54 61
19116719 2009
No effects of bosentan on microvasculature in patients with limited cutaneous systemic sclerosis. 54 61
19350343 2009
Plasma adrenomedullin and endothelin-1 levels are reduced and Raynaud's phenomenon improved by daily tadalafil administration in male patients with systemic sclerosis. 61 54
19321043 2009
Oral phosphodiesterase type 5 inhibitors: nonerectogenic beneficial uses. 61 54
18761597 2008
Comprehensive investigation of novel serum markers of pulmonary fibrosis associated with systemic sclerosis and dermato/polymyositis. 54 61
18578962 2008
Endothelin-1 does not change the function of monocyte-derived dendritic cells grown from patients with systemic sclerosis. 54 61
18991099 2008
[Endothelin-1 in systemic sclerosis]. 61 54
17603692 2007
Clinical manifestations and vascular events in patients with lupus erythematosus anticardiolipin antibodies and raynaud's phenomenon. 54 61
17550096 2006
Endothelin-1, platelets and Raynaud's phenomenon. 61 54
17164754 2006
Phosphodiesterase inhibitors in Raynaud's phenomenon. 54 61
16835313 2006
The role of endothelin-1 and selected cytokines in the pathogenesis of Raynaud's phenomenon associated with systemic connective tissue diseases. 54 61
16763543 2006
Antisynthetase syndrome associated with sarcoidosis. 61 54
17043379 2006
Anti-lactoferrin antibodies in systemic lupus erythematosus: isotypes and clinical correlates. 61 54
15592902 2005
Cooling-induced contraction and protein tyrosine kinase activity of isolated arterioles in secondary Raynaud's phenomenon. 54 61
15695304 2005
Efficacy and tolerability of a selective alpha(2C)-adrenergic receptor blocker in recovery from cold-induced vasospasm in scleroderma patients: a single-center, double-blind, placebo-controlled, randomized crossover study. 54 61
15593189 2004
Severe ADAMTS13 deficiency in adult idiopathic thrombotic microangiopathies defines a subset of patients characterized by various autoimmune manifestations, lower platelet count, and mild renal involvement. 61 54
15232311 2004
Raynaud's phenomenon and antiphospholipid antibodies in systemic lupus erythematosus: is there an association? 54 61
12972482 2003
Increased asymmetric dimethylarginine and endothelin 1 levels in secondary Raynaud's phenomenon: implications for vascular dysfunction and progression of disease. 61 54
12847693 2003
Brachial endothelial function is impaired in patients with systemic lupus erythematosus. 54 61
11842823 2002
[Evidence-based therapy of systemic sclerosis]. 61 54
11826742 2001
Effect of temperature and modulators of protein tyrosine kinase activity on the reactivity of isolated venules in secondary Raynaud's phenomenon. 61 54
11669167 2001
[Endothelin-1 in pathogenesis of Raynaud's syndrome]. 54 61
11503255 2001
Treatment of Raynaud's phenomenon with intravenous prostaglandin E1alpha-cyclodextrin improves endothelial cell injury in systemic sclerosis. 61 54
11327251 2001
Anti-cardiolipin antibodies, Raynaud's phenomenon with digital ischemia, and non small cell carcinoma of the lung. 54 61
11469530 2001
Digital vascular responses and serum endothelin-1 concentrations in primary and secondary Raynaud's phenomenon. 54 61
11053063 2000
Evaluation of vascular injury with proinflammatory cytokines, thrombomodulin and fibronectin in patients with primary fibromyalgia. 61 54
11201985 2000
Homocysteine concentration in primary and systemic sclerosis associated Raynaud's phenomenon. 54 61
11093443 2000
Changes in plasma serotonin concentration and acceleration plethysmograms in patients with Raynaud's phenomenon after long-term treatment with a 5-HT2 receptor antagonist. 61 54
11092268 2000
Thrombosis in patients with connective tissue diseases treated with specific cyclooxygenase 2 inhibitors. A report of four cases. 61 54
10943882 2000
Measurement of soluble adhesion molecules in primary Raynaud's phenomenon and in Raynaud's phenomenon secondary to connective tissue diseases. 54 61
11043500 2000
Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial. 61 54
10616013 1999
[Cardiac disorders associated with progressive systemic sclerosis]. 61 54
9914957 1998
Whole-body cooling increases plasma endothelin-1 levels in women with primary Raynaud's phenomenon. 54 61
9784937 1998
Headache in systemic lupus erythematosus: a controlled study. 54 61
9566671 1998
Mucocutaneous disease in Arabs with systemic lupus erythematosus: clinical expression and relevance to autoantibodies. 54 61
9863895 1998
Cutaneous localization of endothelin-1 in patients with systemic sclerosis: immunoelectron microscopic study. 61 54
9169324 1997
Circulating endothelin-1 levels in patients with "a frigore" vascular acrosyndromes. 61 54
9063031 1996
Endothelin-1 and cold provocation in health, primary Raynaud's phenomenon, and progressive systemic sclerosis. 54 61
8901448 1996
Calcitonin gene-related peptide, endothelin-1, the cutaneous microvasculature and Raynaud's phenomenon. 61 54
8731660 1996
Von Willebrand factor, thrombomodulin, thromboxane, beta-thromboglobulin and markers of fibrinolysis in primary Raynaud's phenomenon and systemic sclerosis. 61 54
8712862 1996
Fibrinolysis and coagulation abnormalities in systemic lupus erythematosus. Relationship with Raynaud's phenomenon, disease activity, inflammatory indices, anticardiolipin antibodies and corticosteroid therapy. 61 54
7724997 1995
Increased endothelin-1 production in fibroblasts derived from patients with systemic sclerosis. 61 54
7944634 1994
[Systemic sclerosis after a long-term follow-up]. 54 61
7936353 1994
Localization of endothelin-1 and its binding sites in scleroderma skin. 54 61
7525957 1994
Anticentromere autoantibodies. Evaluation of an ELISA using recombinant fusion protein CENP-B as antigen. 61 54
8129780 1994
Tissue-type plasminogen activator and von Willebrand factor plasma levels as markers of endothelial involvement in patients with Raynaud's phenomenon. 61 54
1459797 1992
[A case of Sweet's syndrome (acute febrile neutrophilic dermatosis) associated with mixed connective tissue disease]. 54 61
1411796 1992
Effect of total-body cold exposure on plasma concentrations of von Willebrand factor, endothelin-1 and thrombomodulin in systemic lupus erythematosus patients with or without Raynaud's phenomenon. 61 54
1337960 1992

Variations for Raynaud Phenomenon

Expression for Raynaud Phenomenon

Search GEO for disease gene expression data for Raynaud Phenomenon.

Pathways for Raynaud Phenomenon

GO Terms for Raynaud Phenomenon

Biological processes related to Raynaud Phenomenon according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of sensory perception of pain GO:0051930 9.26 EDN1 ADRA2C
2 regulation of vasoconstriction GO:0019229 9.16 EDN1 ADRA2C
3 negative regulation of blood coagulation GO:0030195 8.96 EDN1 APOH
4 negative regulation of smooth muscle cell apoptotic process GO:0034392 8.62 EDN1 APOH

Sources for Raynaud Phenomenon

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
69 Tocris
71 UMLS via Orphanet
Loading form....